We are excited to announce that Biocytogen will be attending World ADC London. This major industry event will bring together over 700 members of the global ADC community in driving progress and collaboration across the value chain. Biocytogen’s CSO, Benny Yang, will be holding a talk on February 24th from 12:30 - 13:00 on RenSuper® Biologics: Empowering Next-Gen Dual-Payload ADCs with AI-Driven Precision and Scalability. This is a great chance to network and learn more about our advancements in biomedical research.
What is World ADC London?
World ADC London is the longest-standing and pre-eminent antibody-drug conjugate conference in Europe. As ADCs move into earlier line therapies and clinical success accelerates, the field is focused on overcoming payload saturation and emerging patient resistance through meaningful differentiation. This event will feature seminars, poster sessions, exhibitions, highlighting the innovations shaping the future of effective ADC therapies for patients worldwide.
Event Overview
Date: February 23rd - 25th, 2026
Venue: Excel London, Royal Victoria Dock, 1 Western Gateway, London E16 1XL, UK
Event Schedule
For more information, please refer to the event agenda.
About BIOCYTOGEN
Biocytogen (SSE: 688796; HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice® platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, nanobody discovery and TCR mimic antibody discovery, and has established a sub-brand, RenBiologics™, to explore global partnerships for an off-the-shelf library of >1,000,000 fully human antibody sequences against over 1000 targets for worldwide collaboration. As of June 30, 2025, approximately 280 therapeutic antibody and multiple clinical asset co-development/out-licensing/transfer agreements and over 50 target-nominated RenMice® licensing projects have been established around the globe, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company's sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA (Boston, San Francisco, San Diego), and Germany (Heidelberg). For more information, please visit https://biocytogen.com.
We look forward to meeting you in London!
